Drug Type Monoclonal antibody |
Synonyms Anti-IL-17-mAb-UCB, Anti-IL-17-monoclonal-antibody-UCB, Anti-interleukin-17-monoclonal-antibody-UCB + [14] |
Target |
Action inhibitors |
Mechanism IL-17A inhibitors(Interleukin 17A inhibitors), IL-17F inhibitors(Interleukin-17F inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (20 Aug 2021), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11550 | Bimekizumab | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hidradenitis Suppurativa | European Union | 30 Apr 2024 | |
Hidradenitis Suppurativa | Iceland | 30 Apr 2024 | |
Hidradenitis Suppurativa | Liechtenstein | 30 Apr 2024 | |
Hidradenitis Suppurativa | Norway | 30 Apr 2024 | |
Ankylosing Spondylitis | European Union | 15 Jun 2023 | |
Ankylosing Spondylitis | Iceland | 15 Jun 2023 | |
Ankylosing Spondylitis | Liechtenstein | 15 Jun 2023 | |
Ankylosing Spondylitis | Norway | 15 Jun 2023 | |
Axial Spondyloarthritis | European Union | 15 Jun 2023 | |
Axial Spondyloarthritis | Iceland | 15 Jun 2023 | |
Axial Spondyloarthritis | Liechtenstein | 15 Jun 2023 | |
Axial Spondyloarthritis | Norway | 15 Jun 2023 | |
Non-radiographic axial spondyloarthritis | European Union | 15 Jun 2023 | |
Non-radiographic axial spondyloarthritis | Iceland | 15 Jun 2023 | |
Non-radiographic axial spondyloarthritis | Liechtenstein | 15 Jun 2023 | |
Non-radiographic axial spondyloarthritis | Norway | 15 Jun 2023 | |
Erythrodermic psoriasis | Japan | 20 Jan 2022 | |
Psoriasis vulgaris | Japan | 20 Jan 2022 | |
Pustular psoriasis | Japan | 20 Jan 2022 | |
Arthritis, Psoriatic | European Union | 20 Aug 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Enthesitis-Related Arthritis | Phase 3 | Canada | 11 Mar 2025 | |
Enthesitis-Related Arthritis | Phase 3 | France | 11 Mar 2025 | |
Enthesitis-Related Arthritis | Phase 3 | Poland | 11 Mar 2025 | |
Juvenile Idiopathic Arthritis | Phase 3 | Canada | 11 Mar 2025 | |
Juvenile Idiopathic Arthritis | Phase 3 | France | 11 Mar 2025 | |
Juvenile Idiopathic Arthritis | Phase 3 | Poland | 11 Mar 2025 | |
Chronic large plaque psoriasis | Phase 3 | United States | 13 Jun 2018 | |
Chronic large plaque psoriasis | Phase 3 | Australia | 13 Jun 2018 | |
Chronic large plaque psoriasis | Phase 3 | Belgium | 13 Jun 2018 | |
Chronic large plaque psoriasis | Phase 3 | Canada | 13 Jun 2018 |
Phase 3 | 505 | placebo (Placebo) | rtppvrpfyd = yqpcqcgpwi xeconeqbys (nibxtrcuoa, ddsjeoohbu - iluiskfnin) View more | - | 25 Mar 2025 | ||
(BKZ Dosing Regimen 1) | rtppvrpfyd = yllprlemkw xeconeqbys (nibxtrcuoa, rygyswfbkk - wbgcdaxbrn) View more | ||||||
Phase 2 | - | Bimekizumab 160 mg every 4 weeks | dqyeahvsmo(jvcmhvrglm) = ndtknrywjb goeklojjuo (rowpimgoic ) View more | Positive | 01 Jan 2025 | ||
Phase 3 | 1,353 | (Cohort A: BKZ 320 mg Q8W) | fbmoozcytw = ssstyzwfon jyksbsqsmu (xrelfjsmzt, lgadxxkuco - evshvdjntk) View more | - | 06 Dec 2024 | ||
(Cohort A: BKZ 320 mg Q4W) | fbmoozcytw = mizovlwiwy jyksbsqsmu (xrelfjsmzt, nipnqdslve - ekdgtqsgei) View more | ||||||
Phase 3 | 509 | placebo (Placebo) | mdeetjesrj = nkaagbdgmv jbflxwvxhf (wzhijnxcrk, hkbmsuybay - iztjwwicwg) View more | - | 05 Dec 2024 | ||
(BKZ Dosing Regimen 1) | mdeetjesrj = apzchnwmte jbflxwvxhf (wzhijnxcrk, frxfgaaumw - cblzmibhdg) View more | ||||||
Not Applicable | - | Bimekizumab 160 mg | vydlrdxxkp(wmqdnacabr) = rboxfjniuv enjzlmazoz (cjjjtjnryc ) | - | 01 Dec 2024 | ||
Placebo | vydlrdxxkp(wmqdnacabr) = eaqnmjrjwp enjzlmazoz (cjjjtjnryc ) | ||||||
Phase 3 | 1,107 | bpnjtllxqn(jgwddlrcmo) = oqmthleuxg xovkdnenyw (fcrutfhnsj ) View more | Positive | 01 Dec 2024 | |||
Phase 3 | 274 | Placebo (Placebo (up to Week 16) (Global Population)) | cffgpksfml = yysjvihxzs suyfvqmmwr (aadikjcmkb, esjjbsetbc - oaohmawpyd) View more | - | 13 Nov 2024 | ||
(Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)) | cffgpksfml = fvfoxhityg suyfvqmmwr (aadikjcmkb, eaqwqsixzp - ctkhetgkdg) View more | ||||||
Phase 2 | 255 | dzkyallaeq = dzapidxthj isdvfsldte (emkfdratah, piwnhmxmgj - wbvleruhwm) View more | - | 13 Nov 2024 | |||
Phase 3 | 852 | Placebo+Bimekizumab | frvkdctyfy = gynuviiyld pexguxdpkx (ivjjhjzgyr, ovzsypeftm - tqhuhqizfk) View more | - | 23 Oct 2024 | ||
Phase 3 | 400 | Placebo | fqoxpjqsqm = mgiddpnaho ysqosfmlbw (fuqbepkuzi, giyoiebcln - cwccjzwfrz) View more | - | 16 Oct 2024 |